Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC sunscreens rule

This article was originally published in The Tan Sheet

Executive Summary

FDA will continue to accept comments on its proposed rule to amend the final monograph for over-the-counter sunscreen products until Dec. 26, the agency announces in a Nov. 28 Federal Register notice. The agency pushed the deadline back by one month in response to requests from parties wanting additional time to submit comments. FDA issued the proposed rule Aug. 23, amending the final monograph to include UVA ray protection standards including in vivo and in vitro tests (1"The Tan Sheet" Aug. 27, 2007, p. 3). The final monograph was issued in 1999, but has consistently been stayed due to pressure from industry...

You may also be interested in...



Sunscreen Proposed Rule May Create UVA Protection Marketing Opportunity

FDA's proposed rule amending its final monograph on sunscreens to include UVA ray protection standards could create new marketing opportunities for manufacturers (see chart: "1Selected Proposed Changes To OTC Sunscreen Monograph")

OTC Sales Of Hearing Aids In US For Mild To Moderate Loss Allowed Under FDA Final Rule

After requirement from Congress and push from President Biden, FDA establishes regulatory category for hearing aids to allow US consumers with mild to moderate hearing loss to purchase the devices without a prescription or prior exam.

Safe Use Of Hydrogen-Peroxide Contact Lens Solution Magnified in US FDA Draft Guidance

Draft guidance pulls from Ophthalmic Devices Panel and Risk Communication Advisory Committee 2017 meeting to discuss more clearly communicating risks of the solutions to consumers while allowing products to remain available OTC.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS101160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel